HR+/HER2-negative Breast CancerPhase 1/2Amelia-1NCT05455619
Evexomostat Plus PI3K or AKT Inhibitor and Fulvestrant in Patients With a PI3K Alteration and HR+/Her2- Breast Cancer
A Phase 1/2 study testing Evexomostat in people with HR+/HER2-negative Breast Cancer and Metastatic Breast Cancer, run by SynDevRx, Inc. at 10 sites in United States.
Trial summary
This is a Phase 1b/2, open-label, parallel-arms pilot study in men and post-menopausal women with hormone receptor positive (HR+), HER2- advanced or metastatic breast cancer with an alteration in the PI3K pathway, including a mutation of the PIK3CA gene, PTEN loss, or AKT1 mutation, designed to determine the safety of… Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- HR+/HER2-negative Breast Cancer, Metastatic Breast Cancer
- What is being tested?
- Evexomostat
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 52 participants
- Where
- 10 sitesUnited States
- Study dates
- 26 Aug 2022to Mar 2027
- Phase
- Phase 1/2
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Patient is an adult male or postmenopausal female ≥18 years old at the time of informed consent(s) and has signed informed consent(s) before any trial related activities and according to local guidelines.
- Patient with histologically and/or cytologically confirmed diagnosis of HR+, HER2- breast cancer, as determined by the local laboratory.
- Patient has identified PI3K pathway alteration, defined as a PIK3CA mutation or PTEN loss or an AKT1 mutation using a Food and Drug Administration (FDA)-approved test, as determined either during Screening or was previously determined to have the alteration as evidenced by written documentation.
- Patient has locally advanced (not amenable to curative therapy or metastatic) breast cancer meeting any of the following categories:
- Relapsed disease, not amenable to curative therapy, with documented evidence of progressive disease (PD) following receipt of both (neo) adjuvant endocrine therapy and a CDK 4/6 inhibitor therapy (either alone or in combination with endocrine therapy) in the early stage or metastatic setting.
- Newly diagnosed advanced breast cancer, with relapsed disease (i.e., documented evidence of PD) while receiving or after endocrine therapy plus a CDK 4/6 inhibitor.
Show all 31Show fewer
- Patient has measurable disease per the Response Evaluation Criteria in Solid Tumors (RECIST) v1.1.
- For bone lesions, lytic bone lesions or mixed lytic-blastic lesions, with identifiable soft tissue components, that can be evaluated by cross-sectional imaging techniques such as computed tomography (CT) or magnetic resonance imaging (MRI) can be considered as measurable lesions if the soft tissue component meets the definition of measurability per RECIST 1.1. Blastic bone lesions are non-measurable.
- For bone metastases only (without measurable lesions), patients may be accrued to the safety Cohorts only.
- Patient has an Eastern Cooperative Oncology Group Performance Status (ECOG-PS) ≤1
- Patient has a Screening fasting plasma glucose (FPG) level ≤140 mg/dL (7.7 mmol/L) and an HbA1c ≤6.4% (47 mmol/mol) for those taking alpelisib, or an HbA1c <8% (64 mmol/mol) for those taking capivasertib.
- Patient has a body mass index (BMI) ≥ 20 kg/m2.
- Patient is male or postmenopausal female. Postmenopausal is defined as any of the following:
- ≥45 years of age and has not had menses for >2 years.
- Amenorrheic for >2 years without a hysterectomy and oophorectomy and a follicle-stimulating hormone value in the postmenopausal range upon pre-study (screening) evaluation.
- Post hysterectomy with oophorectomy. Documented hysterectomy or oophorectomy must be confirmed with medical records of the actual procedure or confirmed by an ultrasound. In case of oophorectomy alone, hormone level assessment (follicle-stimulating hormone, estradiol) will be done locally at Screening to confirm postmenopausal status. Patients who are on ovarian function suppression also qualify.
- Patient is allowed prior fulvestrant treatment, provided they remain eligible for fulvestrant treatment. Patients whose disease progressed while receiving fulvestrant monotherapy are not allowed.
- Patient is allowed prior mTOR or PI3K inhibitor treatment for patients otherwise eligible for capivasertib treatment. Likewise, patient is allowed prior mTOR or AKT treatment if they are otherwise eligible for alpelisib treatment.
- Patient is allowed up to one (1) prior chemotherapy for their metastatic disease.
- Patient agrees to, and is willing and able to arrive at the hospital/clinic in a fasted state (>8 hours) on designated fasting days.
- Patient has adequate bone marrow and organ function as defined by the following laboratory values:
- Platelet count ≥140×109/L
- In absence of liver metastases, alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤2.5×the upper limit of normal (ULN). If the patient has liver metastases, ALT and AST ≤5×ULN.
- Total bilirubin ≤1.5×ULN except for patient with Gilbert's syndrome who may only be included if the total bilirubin is ≤3.0×ULN or direct bilirubin ≤1.5×ULN.
- Fasting serum amylase ≤2×ULN.
- Fasting serum lipase ≤1.5×ULN.
- Hemoglobin ≥ 9 g/dL.
- Absolute neutrophil count (ANC) ≥1500/mL.
- Creatinine clearance ≥ 50 mL/min using either the Cockcroft-Gault equation or the CKD-EPI formula for calculation of eGFR, or has chronic kidney disease (CKD) grade ≤1 as evidenced by a treating nephrologist. Alternatively, a 24-hour urine test can be performed to confirm renal sufficiency.
- Albumin ≥ 3.5 gm/dL.
- Patient is able to take oral medications.
Who cannot join
- Patient has inflammatory breast cancer at screening.
- Patient has known primary brain malignancy, active brain metastasis or active central nervous system pathology or is considered by the Investigator to be neurologically unstable. Furthermore, patients must not have received corticosteroids within 4 weeks of study entry and must have unchanged brain CT or MRI findings for at least two months prior to screening.
- Patient has a known hypersensitivity to evexomostat, fulvestrant, alpelisib, or capivasertib, or to any of their excipients.
- Patient has an established diagnosis of type 1 diabetes mellitus or uncontrolled (based on fasting plasma glucose [FPG] >140mg/dL or HbA1c ≥6.5% for patients assigned alpelisib) or HbA1c for patients assigned to capivasertib, type 2 diabetes or has taken insulin in the 4 weeks prior to C1D1.
- Patient has had major surgery within 30 days or minor surgery within 14 days prior to the first study drug dose, or has not recovered from major side effects from prior surgery.
- Patient has ongoing toxicities related to prior anti-cancer therapies that have not resolved to Grade 0 for bone marrow toxicities or ≤Grade 1 for other toxicities, per National Cancer Institute Common Terminology Criteria for Adverse Events, Version 5.0 (NCI CTCAE v.5.0), with the exception of alopecia.
Show all 24Show fewer
- Patient has a Child Pugh score of B or C.
- Patient has uncontrolled human immunodeficiency virus (HIV) infection.
- Patient has received radio therapy ≤4 weeks or limited field radiation for palliation ≤2 weeks prior to enrollment, and who has not recovered to ≤Grade 1 from related side effects of such therapy (with the exception of alopecia) and/or from whom ≥25 percentage of bone marrow was irradiated.
- Patient has a concurrent malignancy other than breast cancer or had a malignancy other than breast cancer within 2 years of enrollment, with the exception of adequately treated, basal or squamous cell carcinoma, non-melanomatous skin cancer or curatively resected cervical cancer.
- Patient has impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of the drug alpelisib or capivasertib (e.g., ulcerative diseases, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome, gastric bypass or small bowel resection) based on Investigator discretion.
- Patient has currently documented or unresolved pneumonitis/interstitial lung disease (the chest computed tomography [CT] scan performed before start of study treatment for the purpose of tumor assessment should be reviewed to confirm that there are no relevant pulmonary complications present).
- Patient is currently receiving any of the following medications and cannot be discontinued at least 7 days prior to the start of the treatment:
- Strong cytochrome P450 3A4 (CYP3A4) inducers
- Inhibitors of breast cancer resistance protein (BCRP)
- Sulfonylurea-based anti-diabetic drugs (e.g., glipizide, glyburide, etc.)
- Patient has a history of acute pancreatitis within 1 year of screening or past medical history of chronic pancreatitis.
- Patient has unresolved osteonecrosis of the jaw (unless they are being considered for treated with capivasertib - i.e., this exclusion is only for patients being considered for alpelisib).
- Patient has a history of severe cutaneous reaction, such as Stevens-Johnson Syndrome (SJS), erythema multiforme (EM), toxic epidermal necrolysis (TEN), or drug reaction with eosinophilia and systemic symptoms (DRESS).
- Patient is currently receiving or has received systemic corticosteroids ≤2 weeks prior to starting study drug, or who have not fully recovered from side effects of such treatment. Note: The following uses of corticosteroids are permitted: single doses (PO or IV), topical applications (e.g., for rash), inhaled sprays (e.g., for obstructive airways diseases), eye drops or local injections (e.g., intra-articular).
- Patient is nursing (lactating) or pregnant confirmed by a positive serum (hCG) test prior to initiating study treatment.
- Patient participated in a prior investigational study within 21 days prior to the start of study treatment or within 5 half-lives of the investigational product, whichever is longer.
- Patient has any other concurrent, severe and/or uncontrolled medical condition that would, in the Investigator's judgement, contra-indicate patient participation in the clinical study (e.g., chronic active hepatitis, severe hepatic impairment, recent cardiac events, uncontrolled heart disease)
- Patient is not able to understand nor to comply with study instructions and requirements, including fasting requirements.
Trial locations and contacts
10 sites in 1 country. Contact the study team or a site near you to ask about taking part.
10 sites in 1 country
United States10 sites, 10 recruiting
- Recruiting
Cleveland Clinic
Cleveland, Ohio, 44195
Azka Ali, MD
- Recruiting
Penn State Milton S Hershey Medical Center
Hershey, Pennsylvania, 17033
717-531-5471, PSCI-CTO@pennstatehealth.psu.edu
Monali Vasekar, MD
- Recruiting
Hope and Healing Cancer Services
Hinsdale, Illinois, 60521
Srilata Gundala, MD
- Recruiting
Doctors Hospital of Laredo
Laredo, Texas, 78045
Alex Guerrero, 956 693 1301, alejandro.guerrero@uhsinc.com
Eduardo Miranda, MD
- Recruiting
Loma Linda University Cancer Center
Loma Linda, California, 92354
Lorena Garcia, CRC, (909) 651-5612, Lcgarcia@llu.edu
Gayathri Nagaraj, MD
- Recruiting
Miami Cancer Institute at Baptist Health
Miami, Florida, 33176
Xiaoou Pan, xiaoou.pan@baptisthealth.net
Reshma Mahtani, DO
- Recruiting
Vanderbilt University Medical Center
Nashville, Tennessee, 37232
The Vanderbilt-Ingram Cancer Center Patient Contact Line, 1-800-811-8480, cip@vumc.org
Brent Rexer, MD
- Recruiting
Hoag Memorial Hospital Presbyterian
Newport, California, 92663
Patrice Jones, 949-764-5501, patrice.jones@hoag.org
Chaitali Nangia, MD
- Recruiting
SHARP Healthcare
San Diego, California, 92123
Kristen Rice, MD
- Recruiting
Trinity Health
Ypsilanti, Michigan, 48197
Tareq Al Baghdadi, MD
About this study
Official title: Study to Assess the Safety and Efficacy of Evexomostat (SDX-7320) in Combination With A PI3K or Akt Inhibitor Plus Fulvestrant in Patients With HR+, HER2-, Metastatic Breast Cancer With PI3K Pathway Alteration(s)
This is a Phase 1b/2, open-label, parallel-arms pilot study in men and post-menopausal women with hormone receptor positive (HR+), HER2- advanced or metastatic breast cancer with an alteration in the PI3K pathway, including a mutation of the PIK3CA gene, PTEN loss, or AKT1 mutation, designed to determine the safety of evexomostat (SDX-7320) plus standard of care treatment alpelisib (BYL-719) or capivasertib and fulvestrant (each combined, the 'triplet therapy'), to measure the severity and number of hyperglycemic events, and to assess clinical, anti-tumor benefit of the triplet therapy.
The purpose of this study is:
- to characterize the safety of the triplet drug combination consisting of either alpelisib or capivasertib (per the treating oncologist's choice) and fulvestrant plus evexomostat,
- to test whether evexomostat, when given in combination with either alpelisib or capivasertib and fulvestrant will reduce the number and severity of hyperglycemic events and/or reduce the number or dose of anti-diabetic medications needed to control the hyperglycemia for metabolically normal patients and those deemed at risk for capivasertib and alpelisib-induced hyperglycemia (insulin resistance, as measured by HOMA-IR, baseline elevated HbA1c or well-controlled type 2 diabetes), and
- to assess preliminary anti-tumor efficacy for each combination and changes in key biomarkers and quality of life in this patient population.
Read the detailed description
Phosphoinositide 3-kinase (PI3K) pathway alterations frequently occur in breast cancer, conferring growth advantages to cancer cells via increased catalytic activity of various related proteins, such as protein kinase B (AKT) or via the loss of function of the negative regulator phosphatase and tensin homolog (PTEN) (He 2021). Of these alterations, the PIK3CA gene is most frequently mutated, leading to disease aggressiveness and patient mortality. Currently approved treatments targeting this pathway include alpelisib, a small molecule that inhibits the activity of the PIK3CA gene product PI3Kα, and capivasertib, a small molecule that targets the AKT protein. Both molecules have demonstrated similar clinical benefit in cancer patients with genetic alterations that activate the PI3K/Akt/ mammalian target of rapamycin (mTOR) pathway (André 2019, Turner 2023). However, hyperglycemia, a toxicity associated with PI3K and/or Akt inhibition, leads to hyperinsulinemia, re-activating the pathway and thereby limiting each drug's clinical efficacy. Management of hyperglycemia is important to ensure patients receive optimal anti-tumor therapy (Rugo 2020). Restoring insulin sensitivity and reducing levels of insulin have been suggested as ways to blunt the hyperglycemia associated with drugs that inhibit this pathway and have been reported to improve their efficacy (Hopkins 2018, Crouthamel 2009).
The purpose of this study is
- to characterize the safety of the triplet drug combination consisting of either alpelisib or capivasertib (per the treating oncologist's choice) and fulvestrant plus evexomostat,
- to test whether evexomostat, when given in combination with either alpelisib or capivasertib and fulvestrant will reduce the number and severity of hyperglycemic events and/or reduce the number or dose of anti-diabetic medications needed to control the hyperglycemia for metabolically normal patients and those deemed at risk for capivasertib and alpelisib-induced hyperglycemia (insulin resistance, as measured by HOMA-IR, baseline elevated HbA1c or well-controlled type 2 diabetes), and
- to assess preliminary anti-tumor efficacy for each combination and changes in key biomarkers and quality of life in this patient population.
This is a Phase 1b/2, open-label, parallel-arms pilot study in men and post-menopausal women with hormone receptor positive (HR+), HER2- advanced or metastatic breast cancer with an alteration in the PI3K pathway, including a mutation of the PIK3CA gene, PTEN loss, or AKT1 mutation, designed to determine the safety of evexomostat (SDX-7320) plus standard of care treatment alpelisib (BYL-719) or capivasertib and fulvestrant (each combined, the 'triplet therapy'), to measure the severity and number of hyperglycemic events, and to assess clinical, anti-tumor benefit of the triplet therapy.
The study will consist of a 14-day pre-treatment phase of evexomostat plus fulvestrant starting on C1D1 before adding either alpelisib or capivasertib on C1D15. The Triple Therapy treatment schedule is summarized in the following table. Tumor assessments will be conducted as a function of when the triplet therapy starts.
Up to 52 patients for each combination arm may be enrolled, starting with dose-escalation cohorts of up to 6 patients for each combination arm. Once the maximum tolerated dose (MTD) of the triplet therapy has been defined for each combination, additional patients will be enrolled until a total of up to 20 patients have completed at least two cycles of the triplet therapy at that dose and combination. If warranted, up to an additional 20 patients may be enrolled to further characterize the safety profile and/or anti-tumor effect of each triplet therapy.
The planned escalation scheme starts at an evexomostat dose of 36 mg/m2 (one dose below the monotherapy MTD of 49 mg/m2) in combination with either alpelisib or capivasertib and fulvestrant given at the marketed doses. Based on aggregate safety data from the first two cycles of the first 6 patients across each triplet combination, and in the absence of ≥ 2 dose-limiting toxicities (DLTs as defined herein), the Safety Review Committee (SRC), in consultation with the Sponsor and the Investigator(s), may increase the evexomostat dose for the next cohort to 49 mg/m2. In the presence of ≥2 DLTs, the SRC may decrease the evexomostat dose to 27 mg/m2 and may adjust the dose of either alpelisib or capivasertib if warranted. The dose of fulvestrant will not be adjusted. If the evexomostat dose of 49 mg/m2 is determined by the SRC not to be tolerable in combination with either alpelisib or capivasertib and fulvestrant, then current and future patients for only their respective combination treatment will receive evexomostat at 36 mg/m2.
Patients will remain on study for up to 7 cycles to characterize the safety and tolerability of the triplet therapy as well as to capture initial efficacy data (e.g., progression-free survival [PFS] following 6 months of the triplet therapy). Patients will be allowed to continue on the triplet therapy if they are receiving clinical benefit, including stable disease, as determined by their treating oncologist.
- Being tested
- Evexomostat
- Keywords
- hyperglycemia, insulin, glucose, SDX-7320, fulvestrant, apelisib, PIK3CA mutation, evexomostat, HR+ Her2- metastatic breast cancer, hyperinsulinemia, capivasertib, AKT, PTEN
- Medical subject headings
- Breast Neoplasms, Hyperglycemia, Insulin Resistance, Hyperinsulinism
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
EvexomostatDrug
Also called SDX-7320
Evexomostat (SDX-7320) is a synthetic copolymer-drug conjugate of a novel MetAP2 inhibitor.
| Study group | Role | What they receive |
|---|---|---|
| Evexomostat | Experimental | Each subject will receive repeat doses (C1, C2…) for 28-day cycles. Participants may continue on study drug until disease progression, unacceptable toxicity, or other withdrawal criteria is met. Receives: Drug: Evexomostat |
What is being measured
The primary outcome is the main question the study is designed to answer.
Incidence of Adverse Events
Safety and tolerability profile will be assessed by Common Terminology Criteria for Adverse Events v5.0 and summarized by type, frequency, and severity of adverse events of evexomostat dosed in combination with alpelisib plus fulvestrant
Measured: Up to 48 months
Hyperglycemic Events
Severity, number, and proportion of patients with hyperglycemic events
Measured: Up to 42 months
Secondary outcomes (7)
Anti-tumor activity
Number of patients without disease progression
Measured: 6 months
Glucose control
Number and type of anti-diabetic agents needed for glucose control will be measured
Measured: Up to 42 months
Leptin activity
Changes from baseline in plasma levels of fasting leptin will be measured
Measured: Up to 42 months
Adiponectin activity
Changes from baseline in plasma levels of fasting adiponectin will be measured
Measured: Up to 42 months
Angiogenic activity (bFGF/FGF2)
Changes from baseline in plasma levels of angiogenic biomarkers (bFGF/FGF2, VEGFC) will be measured
Measured: Up to 42 months
Angiogenic activity (VEGFC)
Changes from baseline in plasma levels of angiogenic and tumor biomarkers will be measured
Measured: Up to 42 months
Insulin resistance
Changes from baseline in patients at risk for hyperglycemia using the homeostatic model assessment for insulin resistance (HOMA-IR) score of insulin resistance. HOMA-IR score is calculated as follows: (fasting serum insulin (μU/ml) × fasting plasma glucose (mmol per liter)/22.5).
Measured: Up to 42 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted13 Jul 2022
- Study start26 Aug 2022
- Primary completionDec 2026 (estimated)
- Study completionMar 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (2)Papers the sponsor has linked to this study.
- Other trials for HR+/HER2-negative Breast CancerStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 1/2
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 52 participants (estimated)
Sponsor and investigators
- Lead sponsor
- SynDevRx, Inc.
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- Medical Team, Study director, SynDevRx, Inc.
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05455619
- Sponsor's protocol ID
- SDX-0103
- Acronym
- Amelia-1
- Status last verified
- Apr 2026
- First submitted
- 22 Jun 2022
- Last updated
- 22 Apr 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- Yes
- FDA-regulated device
- No
- Individual data sharing
- No
Publications
Rugo HS, Andre F, Yamashita T, Cerda H, Toledano I, Stemmer SM, Jurado JC, Juric D, Mayer I, Ciruelos EM, Iwata H, Conte P, Campone M, Wilke C, Mills D, Lteif A, Miller M, Gaudenzi F, Loibl S. Time course and management of key adverse events during the randomized phase III SOLAR-1 study of PI3K inhibitor alpelisib plus fulvestrant in patients with HR-positive advanced breast cancer. Ann Oncol. 2020 Aug;31(8):1001-1010. doi: 10.1016/j.annonc.2020.05.001. Epub 2020 May 13.
PubMed 32416251Rugo HS, Lacouture ME, Goncalves MD, Masharani U, Aapro MS, O'Shaughnessy JA. A multidisciplinary approach to optimizing care of patients treated with alpelisib. Breast. 2022 Feb;61:156-167. doi: 10.1016/j.breast.2021.12.016. Epub 2021 Dec 27.
PubMed 35016012
Study at a glance
From the registry record, last updated by the sponsor on 22 Apr 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Study to Assess the Safety and Efficacy of Evexomostat (SDX-7320) in Combination With A PI3K or Akt Inhibitor Plus Fulvestrant in Patients With HR+, HER2-, Metastatic Breast Cancer With PI3K Pathway Alteration(s)
- ClinicalTrials.gov ID
- NCT05455619
- Acronym / sponsor ID
- Amelia-1 / SDX-0103
- Keywords
- hyperglycemia, insulin, glucose, SDX-7320, fulvestrant, apelisib, PIK3CA mutation, evexomostat
- Phase
- Phase 1/2
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 52 participants (estimated)
- Lead sponsor
- SynDevRx, Inc.Industry (pharma, biotech, devices)
- Study start
- 26 Aug 2022 (actual)
- Primary completion
- Dec 2026 (estimated)
- Study completion
- Mar 2027 (estimated)
- First posted
- 13 Jul 2022 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This is a Phase 1b/2, open-label, parallel-arms pilot study in men and post-menopausal women with hormone receptor positive (HR+), HER2- advanced or metastatic breast cancer with an alteration in the PI3K pathway, including a mutation of the PIK3CA gene, PTEN loss, or AKT1 mutation, designed to determine the safety of evexomostat (SDX-7320) plus standard of care treatment alpelisib (BYL-719) or capivasertib and fulvestrant (each combined, the 'triplet therapy'), to measure the severity and number of hyperglycemic events, and to assess clinical, anti-tumor benefit of the triplet therapy.
The purpose of this study is:
- to characterize the safety of the triplet drug combination consisting of either alpelisib or capivasertib (per the treating oncologist's choice) and fulvestrant plus evexomostat,
- to test whether evexomostat, when given in combination with either alpelisib or capivasertib and fulvestrant will reduce the number and severity of hyperglycemic events and/or reduce the number or dose of anti-diabetic medications needed to control the hyperglycemia for metabolically normal patients and those deemed at risk for capivasertib and alpelisib-induced hyperglycemia (insulin resistance, as measured by HOMA-IR, baseline elevated HbA1c or well-controlled type 2 diabetes), and
- to assess preliminary anti-tumor efficacy for each combination and changes in key biomarkers and quality of life in this patient population.
Detailed description
Phosphoinositide 3-kinase (PI3K) pathway alterations frequently occur in breast cancer, conferring growth advantages to cancer cells via increased catalytic activity of various related proteins, such as protein kinase B (AKT) or via the loss of function of the negative regulator phosphatase and tensin homolog (PTEN) (He 2021). Of these alterations, the PIK3CA gene is most frequently mutated, leading to disease aggressiveness and patient mortality. Currently approved treatments targeting this pathway include alpelisib, a small molecule that inhibits the activity of the PIK3CA gene product PI3Kα, and capivasertib, a small molecule that targets the AKT protein. Both molecules have demonstrated similar clinical benefit in cancer patients with genetic alterations that activate the PI3K/Akt/ mammalian target of rapamycin (mTOR) pathway (André 2019, Turner 2023). However, hyperglycemia, a toxicity associated with PI3K and/or Akt inhibition, leads to hyperinsulinemia, re-activating the pathway and thereby limiting each drug's clinical efficacy. Management of hyperglycemia is important to ensure patients receive optimal anti-tumor therapy (Rugo 2020). Restoring insulin sensitivity and reducing levels of insulin have been suggested as ways to blunt the hyperglycemia associated with drugs that inhibit this pathway and have been reported to improve their efficacy (Hopkins 2018, Crouthamel 2009).
The purpose of this study is
- to characterize the safety of the triplet drug combination consisting of either alpelisib or capivasertib (per the treating oncologist's choice) and fulvestrant plus evexomostat,
- to test whether evexomostat, when given in combination with either alpelisib or capivasertib and fulvestrant will reduce the number and severity of hyperglycemic events and/or reduce the number or dose of anti-diabetic medications needed to control the hyperglycemia for metabolically normal patients and those deemed at risk for capivasertib and alpelisib-induced hyperglycemia (insulin resistance, as measured by HOMA-IR, baseline elevated HbA1c or well-controlled type 2 diabetes), and
- to assess preliminary anti-tumor efficacy for each combination and changes in key biomarkers and quality of life in this patient population.
This is a Phase 1b/2, open-label, parallel-arms pilot study in men and post-menopausal women with hormone receptor positive (HR+), HER2- advanced or metastatic breast cancer with an alteration in the PI3K pathway, including a mutation of the PIK3CA gene, PTEN loss, or AKT1 mutation, designed to determine the safety of evexomostat (SDX-7320) plus standard of care treatment alpelisib (BYL-719) or capivasertib and fulvestrant (each combined, the 'triplet therapy'), to measure the severity and number of hyperglycemic events, and to assess clinical, anti-tumor benefit of the triplet therapy.
The study will consist of a 14-day pre-treatment phase of evexomostat plus fulvestrant starting on C1D1 before adding either alpelisib or capivasertib on C1D15. The Triple Therapy treatment schedule is summarized in the following table. Tumor assessments will be conducted as a function of when the triplet therapy starts.
Up to 52 patients for each combination arm may be enrolled, starting with dose-escalation cohorts of up to 6 patients for each combination arm. Once the maximum tolerated dose (MTD) of the triplet therapy has been defined for each combination, additional patients will be enrolled until a total of up to 20 patients have completed at least two cycles of the triplet therapy at that dose and combination. If warranted, up to an additional 20 patients may be enrolled to further characterize the safety profile and/or anti-tumor effect of each triplet therapy.
The planned escalation scheme starts at an evexomostat dose of 36 mg/m2 (one dose below the monotherapy MTD of 49 mg/m2) in combination with either alpelisib or capivasertib and fulvestrant given at the marketed doses. Based on aggregate safety data from the first two cycles of the first 6 patients across each triplet combination, and in the absence of ≥ 2 dose-limiting toxicities (DLTs as defined herein), the Safety Review Committee (SRC), in consultation with the Sponsor and the Investigator(s), may increase the evexomostat dose for the next cohort to 49 mg/m2. In the presence of ≥2 DLTs, the SRC may decrease the evexomostat dose to 27 mg/m2 and may adjust the dose of either alpelisib or capivasertib if warranted. The dose of fulvestrant will not be adjusted. If the evexomostat dose of 49 mg/m2 is determined by the SRC not to be tolerable in combination with either alpelisib or capivasertib and fulvestrant, then current and future patients for only their respective combination treatment will receive evexomostat at 36 mg/m2.
Patients will remain on study for up to 7 cycles to characterize the safety and tolerability of the triplet therapy as well as to capture initial efficacy data (e.g., progression-free survival [PFS] following 6 months of the triplet therapy). Patients will be allowed to continue on the triplet therapy if they are receiving clinical benefit, including stable disease, as determined by their treating oncologist.
Study design
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Evexomostat | Experimental | Drug: EvexomostatEach subject will receive repeat doses (C1, C2…) for 28-day cycles. Participants may continue on study drug until disease progression, unacceptable toxicity, or other withdrawal criteria is met. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (31 listed)
- Patient is an adult male or postmenopausal female ≥18 years old at the time of informed consent(s) and has signed informed consent(s) before any trial related activities and according to local guidelines.
- Patient with histologically and/or cytologically confirmed diagnosis of HR+, HER2- breast cancer, as determined by the local laboratory.
- Patient has identified PI3K pathway alteration, defined as a PIK3CA mutation or PTEN loss or an AKT1 mutation using a Food and Drug Administration (FDA)-approved test, as determined either during Screening or was previously determined to have the alteration as evidenced by written documentation.
- Patient has locally advanced (not amenable to curative therapy or metastatic) breast cancer meeting any of the following categories:
- Patient has measurable disease per the Response Evaluation Criteria in Solid Tumors (RECIST) v1.1.
Key exclusion criteria (24 listed)
- Patient has inflammatory breast cancer at screening.
- Patient has known primary brain malignancy, active brain metastasis or active central nervous system pathology or is considered by the Investigator to be neurologically unstable. Furthermore, patients must not have received corticosteroids within 4 weeks of study entry and must have unchanged brain CT or MRI findings for at least two months prior to screening.
- Patient has a known hypersensitivity to evexomostat, fulvestrant, alpelisib, or capivasertib, or to any of their excipients.
- Patient has an established diagnosis of type 1 diabetes mellitus or uncontrolled (based on fasting plasma glucose [FPG] >140mg/dL or HbA1c ≥6.5% for patients assigned alpelisib) or HbA1c for patients assigned to capivasertib, type 2 diabetes or has taken insulin in the 4 weeks prior to C1D1.
- Patient has had major surgery within 30 days or minor surgery within 14 days prior to the first study drug dose, or has not recovered from major side effects from prior surgery.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| EvexomostatAlso: SDX-7320Evexomostat (SDX-7320) is a synthetic copolymer-drug conjugate of a novel MetAP2 inhibitor. | Drug | Evexomostat |
Primary outcome
Incidence of Adverse Events
Time frame: Up to 48 months
Safety and tolerability profile will be assessed by Common Terminology Criteria for Adverse Events v5.0 and summarized by type, frequency, and severity of adverse events of evexomostat dosed in combination with alpelisib plus fulvestrant
Hyperglycemic Events
Time frame: Up to 42 months
Severity, number, and proportion of patients with hyperglycemic events
7 secondary outcomes
Anti-tumor activity
Time frame: 6 months
Glucose control
Time frame: Up to 42 months
Leptin activity
Time frame: Up to 42 months
Adiponectin activity
Time frame: Up to 42 months
Angiogenic activity (bFGF/FGF2)
Time frame: Up to 42 months
Angiogenic activity (VEGFC)
Time frame: Up to 42 months
Insulin resistance
Time frame: Up to 42 months
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 22 Apr 2026.
- Results publication: PubMed 32416251Rugo HS, Andre F, Yamashita T, Cerda H, Toledano I, Stemmer SM, Jurado JC, Juric D, Mayer I, Ciruelos EM, Iwata H, Conte P, Campone M, Wilke C, Mills D, Lteif A, Miller M, Gaudenzi F, Loibl S. Time course and management of key adverse events during the randomized phase III SOLAR-1 study of PI3K inhibitor alpelisib plus fulvestrant in patients with HR-positive advanced breast cancer. Ann Oncol. 2020 Aug;31(8):1001-1010. doi: 10.1016/j.annonc.2020.05.001. Epub 2020 May 13.
- Results publication: PubMed 35016012Rugo HS, Lacouture ME, Goncalves MD, Masharani U, Aapro MS, O'Shaughnessy JA. A multidisciplinary approach to optimizing care of patients treated with alpelisib. Breast. 2022 Feb;61:156-167. doi: 10.1016/j.breast.2021.12.016. Epub 2021 Dec 27.
- Individual participant dataSharing planned: No
Related trials for HR+/HER2-negative Breast Cancer
Active, not recruitingPhase 1/2
Study of Oral MRT-2359 in Selected Cancer Patients
NSCLC, SCLC
RecruitingPhase 3
Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer
Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8
Not yet recruitingPhase 1
A Study to Evaluate the Effects of GDC-4198 in Combination With Letrozole, Fulvestrant, or Giredestrant in Participants With Locally Advanced or Metastatic Hormone Receptor-Positive, HER2-Negatve Breast Cancer
Advanced or Metastatic Breast Cancer
RecruitingPhase 3
Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer
PIK3CA Mutation, HER2- Negative Breast Cancer
Not yet recruiting
Prospective Study to Evaluate the Clinical Utility of ctDNA Tumor Fraction (TF) for Detection of Estrogen Receptor 1 (ESR1) Mutations in (Human Epidermal Growth Factor Receptor) HR+/HER2- Metastatic Breast Cancer (MBC)
Breast Cancer, Metastatic Breast Cancer
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Medical Team study director
SynDevRx, Inc.
10 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 1/2 study testing Evexomostat in people with HR+/HER2-negative Breast Cancer and Metastatic Breast Cancer, run by SynDevRx, Inc. at 10 sites in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 31 inclusion and 24 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 22 Apr 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 10 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this combined phase mean?
Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.
Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact David Browning (+1-615-975-7776, dbrowning@syndevrx.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Incidence of Adverse Events (time frame: Up to 48 months). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT05455619, which also lists 2 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 22 Apr 2026.